• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Impact of chronic kidney disease on major bleeding complications and mortality in patients with indication for oral anticoagulation undergoing coronary stenting.

作者信息

Manzano-Fernández Sergio, Marín Francisco, Pastor-Pérez Francisco J, Caro Cesar, Cambronero Francisco, Lacunza Javier, Pinar Eduardo, Pascual-Figal Domingo A, Valdés Mariano, Lip Gregory Y H

机构信息

Department of Cardiology, University Hospital Virgen de la Arrixaca, Murcia, Spain.

University Department of Medicine, City Hospital, Birmingham, UK.

出版信息

Chest. 2009 Apr;135(4):983-990. doi: 10.1378/chest.08-1425. Epub 2008 Nov 18.

DOI:10.1378/chest.08-1425
PMID:19017872
Abstract

BACKGROUND

Patients with indications for oral anticoagulation (OAC) undergoing percutaneous coronary artery stenting (PCI-S) represent a high-risk population for major bleeding complications. Chronic kidney disease (CKD) is also associated with poor outcome after PCI-S. Limited data are available regarding the impact of CKD on the frequency of major bleeding and mortality in this population.

METHODS

We investigated the influence of CKD on major bleeding and all-cause mortality in patients with indication for OAC who undergo PCI-S. Patients were grouped according to calculated creatinine clearance (CrCl): CrCl > 60 mL/min, (n = 98) and CrCl < or = 60 mL/min, (n = 68). Major bleeding and major adverse vascular events (all-cause mortality, myocardial infarction, repeat revascularization, stent thrombosis, or stroke) were collected during follow-up.

RESULTS

We analyzed 166 consecutive patients with indication(s) for OAC (77% men; mean age, 71 years; range, 66 to 76 years) after undergoing PCI-S. CKD was associated with higher risk for major bleeding (hazard ratio [HR], 3.44; 95% confidence interval [CI], 1.50 to 7.93; p = 0.004) and all-cause mortality (HR, 3.50; 95% CI, 1.53 to 7.99; p = 0.003). In multivariate analyses, age > 75 years (HR, 2.75; 95% CI, 1.15 to 6.56; p = 0.023), CKD (HR, 2.59; 95% CI, 1.00 to 6.95; p = 0.049), anemia (HR, 2.36; 95% CI, 1.00 to 5.54; p = 0.049), and triple antithrombotic therapy (HR, 3.29; 95% CI, 1.23 to 8.84; p = 0.018) were independent predictors for major bleeding, whereas age > 75 years (HR, 2.38; 95% CI, 1.03 to 5.59; p = 0.046) and CKD (HR, 2.44; 95% CI, 1.03 to 5.82; p = 0.044) were predictors for all-cause mortality.

CONCLUSION

In this high-risk population, CKD is independently associated with increased major bleeding and all-cause mortality following PCI-S.

摘要

相似文献

1
Impact of chronic kidney disease on major bleeding complications and mortality in patients with indication for oral anticoagulation undergoing coronary stenting.
Chest. 2009 Apr;135(4):983-990. doi: 10.1378/chest.08-1425. Epub 2008 Nov 18.
2
Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting.在接受经皮冠状动脉支架置入术的心房颤动患者中,与三联抗栓治疗使用相关的严重出血并发症增加。
Chest. 2008 Sep;134(3):559-567. doi: 10.1378/chest.08-0350. Epub 2008 Jul 18.
3
Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention.心肌梗死后和冠状动脉介入治疗后的心房颤动患者的口服抗凝和抗血小板治疗。
J Am Coll Cardiol. 2013 Sep 10;62(11):981-9. doi: 10.1016/j.jacc.2013.05.029. Epub 2013 Jun 7.
4
Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score?对于高 HAS-BLED 出血风险评分的接受冠状动脉支架置入术的房颤患者,我们是否应该推荐口服抗凝治疗?
Circ Cardiovasc Interv. 2012 Aug 1;5(4):459-66. doi: 10.1161/CIRCINTERVENTIONS.112.968792. Epub 2012 Jul 10.
5
Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis.426例接受经皮冠状动脉介入治疗和支架植入术的心房颤动患者的抗凝和抗血小板治疗:对出血风险和预后的影响
J Am Coll Cardiol. 2008 Feb 26;51(8):818-25. doi: 10.1016/j.jacc.2007.11.035.
6
Association of chronic kidney disease with clinical outcomes after coronary revascularization: the Arterial Revascularization Therapies Study (ARTS).慢性肾脏病与冠状动脉血运重建术后临床结局的关联:动脉血运重建治疗研究(ARTS)
Am Heart J. 2005 Mar;149(3):512-9. doi: 10.1016/j.ahj.2004.10.010.
7
Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial.在接受直接经皮冠状动脉介入治疗的 ST 段抬高型心肌梗死患者中慢性肾脏病的长期影响:HORIZONS-AMI(急性心肌梗死中血运重建和支架与优化结果的临床试验)研究。
JACC Cardiovasc Interv. 2011 Sep;4(9):1011-9. doi: 10.1016/j.jcin.2011.06.012.
8
A prospective multicentre observational study on the management of patients on oral anticoagulation undergoing coronary artery stenting: rationale and design of the ongoing warfarin and coronary stenting (WAR-STENT) registry.一项关于接受冠状动脉支架置入术的口服抗凝治疗患者管理的前瞻性多中心观察性研究:正在进行的华法林与冠状动脉支架置入术(WAR-STENT)注册研究的原理与设计。
J Cardiovasc Med (Hagerstown). 2009 Feb;10(2):200-3. doi: 10.2459/JCM.0b013e3283212f07.
9
Meta-analysis of trials comparing oral anticoagulation and aspirin versus dual antiplatelet therapy after coronary stenting. Clues for the management of patients with an indication for long-term anticoagulation undergoing coronary stenting.冠状动脉支架置入术后口服抗凝药与阿司匹林对比双联抗血小板治疗的试验荟萃分析。对有长期抗凝指征且接受冠状动脉支架置入术患者的管理提示。
Cardiology. 2005;104(2):101-6. doi: 10.1159/000086918. Epub 2005 Jul 12.
10
Synergic impact of oral anticoagulation control and renal function in determining major adverse events in atrial fibrillation patients undergoing percutaneous coronary intervention: insights from the AFCAS registry.口服抗凝控制与肾功能对接受经皮冠状动脉介入治疗的房颤患者发生主要不良事件的协同影响:来自AFCAS注册研究的见解
Clin Res Cardiol. 2017 Jun;106(6):420-427. doi: 10.1007/s00392-016-1071-0. Epub 2017 Jan 11.

引用本文的文献

1
Association Between CKD and Major Hemorrhage in Older Persons: Data From the Aspirin in Reducing Events in the Elderly Randomized Trial.慢性肾脏病与老年人重大出血之间的关联:来自阿司匹林减少老年人事件随机试验的数据。
Kidney Int Rep. 2023 Jan 19;8(4):737-745. doi: 10.1016/j.ekir.2023.01.012. eCollection 2023 Apr.
2
Increased concentrations of platelet- and endothelial-derived microparticles in patients with myocardial infarction and reduced renal function- a descriptive study.在心肌梗死和肾功能降低的患者中,血小板和内皮细胞衍生的微颗粒浓度增加——一项描述性研究。
BMC Nephrol. 2019 Mar 1;20(1):71. doi: 10.1186/s12882-019-1261-x.
3
Evaluation of influence of chronic kidney disease and sodium disturbances on clinical course of acute and sub-acute stage first-ever ischemic stroke.
评估慢性肾脏病和钠紊乱对首次发生的急性及亚急性期缺血性卒中临床病程的影响。
Med Sci Monit. 2014 Aug 7;20:1389-94. doi: 10.12659/MSM.890627.
4
[Percutaneous coronary angioplasty in women: clinical, procedural and prognostic features].[女性经皮冠状动脉腔内血管成形术:临床、操作及预后特征]
Pan Afr Med J. 2011;9:44. doi: 10.4314/pamj.v9i1.71223. Epub 2011 Aug 24.
5
Association between CHADS₂risk factors and anticoagulation-related bleeding: a systematic literature review.CHADS₂风险因素与抗凝相关出血的关联:系统文献回顾。
Mayo Clin Proc. 2011 Jun;86(6):509-21. doi: 10.4065/mcp.2010.0755.
6
Fatal renal bleeding in a patient treated with aggressive antithrombotic therapy after recurrent coronary stent thrombosis.反复发生冠状动脉支架血栓形成后采用强化抗血栓治疗的患者发生致命性肾出血。
Korean Circ J. 2010 Jul;40(7):348-51. doi: 10.4070/kcj.2010.40.7.348. Epub 2010 Jul 26.